BioXcel Therapeutics (BTAI) investor relations material

Executive summary

• Net loss for Q1 2026 was $12.7 million, up from $7.3 million in Q1 2025, with revenues of $0.2 million from IGALMI® sales and continued high operating expenses.

• Cash, cash equivalents, and restricted cash totaled $17.2 million as of March 31, 2026, with negative working capital of $21.1 million and a stockholders' deficit of $105.5 million.

• Achieved a major regulatory milestone with FDA acceptance of sNDA for IGALMI® for at-home use, with a PDUFA target action date of November 14, 2026.

• Management has identified substantial doubt about the company's ability to continue as a going concern for at least 12 months from the financial statement issuance date.

• Engaged MTS Health Partners to evaluate strategic options, including potential sale, merger, or partnership to maximize shareholder value.

Financial highlights

• Product revenue, net, was $206,000 in Q1 2026, up from $168,000 in Q1 2025, driven by increased volume and deeper GPO discounts.

• Operating expenses rose to $10.4 million in Q1 2026 from $10.3 million in Q1 2025, with higher cost of goods sold and SG&A offset by lower R&D.

• Cost of goods sold increased to $283,000 from $14,000 year-over-year, mainly due to higher reserves for excess or obsolete inventory.

• Research and development expenses decreased to $3.0 million from $4.6 million, reflecting completion of the SERENITY At-Home Phase 3 trial.

• SG&A expenses rose to $7.2 million from $5.7 million, primarily due to increased professional fees.

Outlook and guidance

• Preparing for IGALMI's commercial launch in the at-home setting, with a comprehensive launch plan and market assessment indicating a large addressable market.

• Management expects continued operating losses and negative cash flows, with a need for substantial additional funding to support ongoing operations and development programs.

• Cash runway is projected into the second quarter of 2026, after which additional capital will be required.

• The board is evaluating strategic options, including sale, merger, collaboration, or continued standalone operations.

• Focused on advancing BXCL501 for Alzheimer's agitation, leveraging a favorable regulatory environment.